4//SEC Filing
IMPAX LABORATORIES INC 4
Accession 0001437749-15-016752
CIK 0001003642operating
Filed
Aug 31, 8:00 PM ET
Accepted
Sep 1, 6:30 PM ET
Size
19.4 KB
Accession
0001437749-15-016752
Insider Transaction Report
Form 4
MARKBREITER MICHAEL
Director
Transactions
- Exercise/Conversion
Common Stock
2015-08-28$17.99/sh+8,000$143,920→ 16,200 total - Sale
Common Stock
2015-08-28$42.48/sh−8,000$339,840→ 8,200 total - Exercise/Conversion
Common Stock
2015-08-31$20.90/sh+10,000$209,000→ 18,200 total - Sale
Common Stock
2015-08-31$41.39/sh−10,000$413,900→ 8,200 total - Exercise/Conversion
Stock Option (Right to Buy)
2015-08-28−8,000→ 4,000 totalExercise: $17.99Exp: 2023-05-15→ Common Stock (8,000 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
2015-08-31−10,000→ 0 totalExercise: $20.90Exp: 2022-05-23→ Common Stock (10,000 underlying) - Exercise/Conversion
Common Stock
2015-08-31$20.30/sh+10,000$203,000→ 18,200 total - Sale
Common Stock
2015-08-31$41.39/sh−10,000$413,900→ 8,200 total - Exercise/Conversion
Stock Option (Right to Buy)
2015-08-31−10,000→ 0 totalExercise: $20.30Exp: 2020-05-26→ Common Stock (10,000 underlying)
Footnotes (5)
- [F1]The price reported in Column 4 is a weighted average price. These shares were sold at prices ranging from $42.29 to $42.71 in multiple transactions. The reporting person undertakes to provide to Impax Laboratories, Inc., any security holder of Impax Laboratories, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold at prices ranging from $40.39 to $42.75 in multiple transactions. The reporting person undertakes to provide to Impax Laboratories, Inc., any security holder of Impax Laboratories, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold at prices ranging from $40.39 to $42.75 in multiple transactions. The reporting person undertakes to provide to Impax Laboratories, Inc., any security holder of Impax Laboratories, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4.
- [F4]Of the 12,000 shares underlying the options, 8,000 of the shares subject to the option are fully vested and exercisable.
- [F5]100% of the shares subject to the option are fully vested and exercisable.
Documents
Issuer
IMPAX LABORATORIES INC
CIK 0001003642
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0001003642
Filing Metadata
- Form type
- 4
- Filed
- Aug 31, 8:00 PM ET
- Accepted
- Sep 1, 6:30 PM ET
- Size
- 19.4 KB